Nucorion Pharmaceuticals is a clinical-stage pharmaceutical company established in 2015. Its lead clinical-stage candidate is NCO-48 Fumarate, a prodrug developed with proprietary LTP Technology for the treatment of Chronic Hepatitis B. Hundreds of millions of people around the world suffer from hepatitis. According to studies, more than 300 millions people worldwide are carriers of Hepatitis B. Long-standing liver infections caused by Hepatitis B and C and cirrhosis as a result of alcohol abuse or metabolic dysfunction also lead to hepatocellular carcinoma (HCC). HCC is a leading cause of cancer-related deaths worldwide, in part because it is often diagnosed at an advanced stage when curative options like surgical resection or transplantation are limited.